Lv12
34 积分 2023-02-05 加入
Nephrotoxicity of immune checkpoint inhibitor combination therapy in patients with advanced renal cell carcinoma: a meta-analysis
1小时前
已完结
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial
1天前
已完结
The Physiological Effects of Air Pollution: Particulate Matter, Physiology and Disease
1天前
已完结
Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study
1天前
已完结
Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer
3天前
已完结
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
13天前
已完结
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
13天前
已完结
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
18天前
已完结
Recent updates in treating carbapenem-resistant infections in patients with hematological malignancies
19天前
已完结
Real-world effectiveness of ceftazidime/avibactam versus polymyxin B in treating patients with carbapenem-resistant Gram-negative bacterial infections
20天前
已完结
皖公网安备34019202002308
